|

GemCis plus PD-1/PD-L1 inhibitor Clinical Trials

1 actively recruiting trial

Top Sponsors

  • Fudan University1

Indications

  • Advanced Biliary Tract Cancer1
  • Cancer1

Other1 trial

GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.